Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

10.40 -0.17 (-1.61%)
Streaming Delayed Price Updated: 11:29 AM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,726
Open 9.280
Bid (Size) 10.33 (1)
Ask (Size) 10.60 (2)
Prev. Close 10.57
Today's Range 9.280 - 10.58
52wk Range 7.650 - 32.40
Shares Outstanding 240,471,497
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314
Lyell Immunopharma reports Q2 2025 with a narrower loss than expected, driven by cost controls. Clinical progress for CAR T-cell therapy LYL314 remains strong, with pivotal trials advancing. Cash... 
Via Chartmill
Topics Earnings
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire

Performance

YTD
-19.4%
-19.4%
1 Month
+7.5%
+7.5%
3 Month
+28.5%
+28.5%
6 Month
-4.6%
-4.6%
1 Year
-61.8%
-61.8%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
Via Benzinga
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Here are the top movers in Thursday's session.
Via Chartmill
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
What's going on in today's session
Via Chartmill
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
What's going on in today's session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Lyell Immunopharma, Inc. - Common Stock publicly traded?
Yes, Lyell Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Lyell Immunopharma, Inc. - Common Stock trade on?
Lyell Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lyell Immunopharma, Inc. - Common Stock?
The ticker symbol for Lyell Immunopharma, Inc. - Common Stock is LYEL on the Nasdaq Stock Market
What is the current price of Lyell Immunopharma, Inc. - Common Stock?
The current price of Lyell Immunopharma, Inc. - Common Stock is 10.40
When was Lyell Immunopharma, Inc. - Common Stock last traded?
The last trade of Lyell Immunopharma, Inc. - Common Stock was at 08/13/25 11:29 AM ET
What is the market capitalization of Lyell Immunopharma, Inc. - Common Stock?
The market capitalization of Lyell Immunopharma, Inc. - Common Stock is 2.50B
How many shares of Lyell Immunopharma, Inc. - Common Stock are outstanding?
Lyell Immunopharma, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.